Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta MSC-derived exosome injections for complex perianal fistula
IRCT20211212053361N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Human placenta mesenchymal stem cell-derived exosomes in anal fistula, sponsored by Tehran University of Medical Sciences. Primary endpoints: Discharge amount, External orifice re-epithelialization and 4 more. Started Dec 2021; status: completed.
02
Drugs
Human placenta mesenchymal stem cell-derived exosomes
03
Conditions
anal fistula
Beyond the preview
Go deeper on IRCT20211212053361N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211212053361N1.